SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending with heavy debate around its valuation after earnings, with some traders pointing to a high P/E ratio while others highlight strong growth and government contracts as bullish signals. Community chatter also mentions Michael Burry's reported short position adding to bearish sentiment. Discussions include potential price movements and whether the stock is overhyped or poised for further gains.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions about government shutdowns, potential impacts on SNAP benefits, and concerns about the company's financials. Community members are actively debating the stock's long-term viability, potential for scams, and the political implications surrounding the Trump Media & Technology Group Corp. There are also discussions regarding Donald Trump and his involvement in the company, alongside the stock's performance compared to broader market trends.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending as part of a broader conversation around privacy coins, with some community members drawing comparisons to ZEC's recent price action.  Enthusiasm is building around DASH's limited supply and potential for significant gains, while others point to its possible use cases and developments.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending downwards following disappointing data from a confirmatory DMD trial, sparking concerns about the future of its PMO therapies; however, the community is debating whether the market reaction is overblown, given the potential for Elevidys to replace these therapies and the company's strong revenue. Some traders are seeing a buying opportunity amidst the dip, while others express concerns about management and potential regulatory hurdles.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending, with community members pointing to recent price movement and speculation around its technology. Discussions revolve around the potential for a significant run, comparisons to other cryptocurrencies, and the impact of upcoming developments like Caffeine AI. Some community members are noting ICP's strong performance relative to other cryptocurrencies.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending downwards, with community members expressing concerns about increased AI spending and questioning the lack of clear monetization timelines which are causing investors to worry. Many are discussing potential support levels and whether the stock is oversold while also noting a significant increase in short interest. Some traders are sharing their bearish outlook, while others remain bullish, viewing the dip as a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid after-hours volatility following its Q3 earnings release, with community chatter focused on revenue, subscriber growth, and a potential deal with Novo Nordisk. The stock's high trading volume and short interest are contributing to speculation about a possible short squeeze. Investors are closely monitoring the company's growth prospects and strategic partnerships in the competitive telehealth sector.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as the crypto community eyes its privacy features and limited supply, drawing comparisons to Bitcoin. Bullish sentiment is fueled by anticipation of a potential short squeeze and speculation around a possible integration with X (formerly Twitter). Some investors are also discussing a rotation from Bitcoin and other major cryptos into Zcash.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending ahead of earnings, with community discussions focused on the company's potential for surprising results despite a pre-released earnings report. Some investors are optimistic about Q2 2026 guidance and increased custom server build margins driving future growth, while others are wary of insider selling and potential volatility, especially as it relates to the CEO's communication style on the earnings call. The stock's connection to the broader AI server market and its relationship with companies like NVDA and AMD also remain a key talking point.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark ($KMB) is trending due to a proposed $48.7 billion acquisition of Kenvue ($KVUE), with shareholders receiving cash and stock. The community is debating the deal's merits, potential Tylenol lawsuit risks, and whether KMB overpaid, while some see it as a generational buying opportunity amidst baseless legal/political concerns. CEO interview also generating buzz, along with potential stock price implications.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN Faruqi & Faruqi Reminds Biohaven Investors of the Pending...

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky

Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi & Korsinsky Class Action Filed Against Biohaven Ltd. (BHVN) Seeking Recovery for Investors - Contact Levi...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related to R&amp;D deals and milestone payments.&nbsp;The expense is set to shave&nbsp;off about $0.26 off its per-share earnings, both on a GAAP and adjusted basis.The update adds to investor caution following the FDA’s recent signal report published on June 30, which named Biogen’s Alzheimer’s treatment Leqembi as one of several drugs flagged for potential post-marketing safety concerns.&nbsp;The report, compiled from the FDA’s FAERS database, represents a push for increased transparency around adverse event reporting.Analysts at RBC Capital said they do not anticipate major regulatory fallout, noting that the data was already publicly available and the risks broadly acknowledged.&nbsp;However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta, Alkermes, Biohaven, Xenon, and Argenx.<a href="https://stocktwits.com/symbol/BIIB">Biogen’s</a> newly itemized R&amp;D charges follow its Q1 decision to present such costs as a separate line item on its income statement.&nbsp;The company stated that these typically include expenses from licensing deals and asset acquisitions, which are accounted for as in-process research and development.Meanwhile, Biogen is advancing its drug pipeline, beginning a Phase 3 study with felzartamab, which can treat a kidney condition known as primary membranous nephropathy.The trial, dubbed Prominent, began dosing patients late last month and will enroll about 180 adults.On Stocktwits, retail sentiment for Biogen was ‘bullish’ amid ‘low’ message volume.Biogen’s stock has declined 13.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Equity

Biohaven Pharma stock tumbles after withdrawal of Dazluma application in EU

Investing.com -- Biohaven Pharma (NYSE: BHVN) shares fell sharply by as much as 21% as the company withdrew its marketing authorization application for Dazluma in Europe, intended to treat spinocerebellar ataxia genotype 3 (SCA3). The stock's downturn followed a brief trading halt due to volatility.

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia Biohaven Announces FDA Acceptance and Priority Review of...

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation P

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective...

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn., Jan. 7, 2025 NEW HAVEN...

Shares of Biohaven (BHVN) gained in morning trade on Tuesday after the company’s director John W. Childs acquired shares worth $1.04 million on Monday.According <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1935979/000193597924000088/xslF345X05/wk-form4_1735646406.xml">to</a> Biohaven’s U.S. Securities and Exchange Commission (SEC) filing, Childs acquired 29,000 shares of the company for the benefit of John W. Childs Revocable Trust, at an average price of $35.9446 apiece, over 3% lower than the current market price of $37.07.Biohaven is a Connecticut-based biopharmaceutical company that focuses on the discovery and development of drugs across therapeutic areas like neuroscience, immunology, and oncology.Earlier this month, the company reported that it achieved essential milestones in the trial of its experimental drug BHV-1300, intended for use in treating a kidney disease. Biohaven also has other trials underway to treat autoimmune diseases.Analysts at RBC Capital raised their price target for the Biohaven stock to $61 from $58 while maintaining an ‘Outperform’ rating, according to TheFly.However, in November, the company’s spinal muscular atrophy (SMA) trial misfired after it failed to achieve its primary endpoint.Reacting to the news of Childs acquiring company shares, Biohaven stock gained over 4% in morning trade on Tuesday, before paring some of the gains.Retail sentiment on Stocktwits entered the ‘bullish’ territory (58/100), with message volume picking up, too.<figure class="image"><img style="aspect-ratio:649/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_31_213107_8d3615ce5c.jpg" alt="BHVN stock sentiment" width="649" height="147"><figcaption>BHVN sentiment and message volume December 31, 2024, as of 11:30 am ET | Source: Stocktwits</figcaption></figure>Overall, though, Biohaven’s shares are down nearly 18.5% over the past month, and 13% year-to-date.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/axsome-therapeutics-stock-tumbles-as-alzheimer-studies-reveal-mixed-results/cJOiJFyRki">Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish

Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.88	--	--	N/A
Q2 '25	-$1.90	-$1.94	-1.99%	MISSED
Q1 '25	-$1.70	-$2.17	-27.62%	MISSED
Q4 '24	-$1.57	-$1.85	-17.47%	MISSED
Q3 '24	-$1.70	-$1.70	0.09%	BEAT

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd